150 related articles for article (PubMed ID: 28319080)
1. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
Nair AP; Walker P; Kalff A; Bergin K; Hocking J; Avery S; Curtis DJ; Patil S; Das T; Klarica D; Morgan S; Muirhead J; Gorniak M; Reynolds J; Spencer A
Bone Marrow Transplant; 2017 Jun; 52(6):839-845. PubMed ID: 28319080
[TBL] [Abstract][Full Text] [Related]
2. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Wei M; Xie C; Huang J; Liu Q; Lai Y
Hematology; 2023 Dec; 28(1):2269509. PubMed ID: 37850613
[TBL] [Abstract][Full Text] [Related]
3. Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis.
Yadav N; Mirgh SP; Aggarwal M; Agrawal N; Mehta P; Khushoo V; Kapoor J; Bhatia N; Agrawal P; Ahmed R; Bhurani D
Indian J Cancer; 2023; 60(3):316-324. PubMed ID: 37787191
[TBL] [Abstract][Full Text] [Related]
4. [The therapeutic effect and prognostic value of oligoclonal bands after autologous stem cell transplant in patients with multiple myeloma].
Shi QL; Xu Y; Wang J; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):514-520. PubMed ID: 38317363
[No Abstract] [Full Text] [Related]
5. Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis.
Tangen JM; Tjønnfjord GE; Gulbrandsen N; Gedde-Dahl T; Stormorken E; Anderson K; Vo CD; Schjesvold FH;
BMC Cancer; 2018 Aug; 18(1):801. PubMed ID: 30089450
[TBL] [Abstract][Full Text] [Related]
6. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma.
Abudayyeh A; Lin H; Mamlouk O; Abdelrahim M; Saliba R; Rondon G; Martinez CS; Delgado R; Page V; Rajasekaran A; Sanders PW; Qazilbash M
Leuk Lymphoma; 2020 Dec; 61(13):3101-3111. PubMed ID: 32723196
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma.
Schmidt WM; Perera ND; Buadi FK; Hayman SR; Kumar SK; Dispenzieri A; Dingli D; Cook J; Lacy MQ; Kapoor P; Leung N; Muchtar E; Warsame RM; Kourelis T; Binder M; Gonsalves WI; Hogan WJ; Gertz MA
Blood Cancer J; 2023 Aug; 13(1):126. PubMed ID: 37591876
[TBL] [Abstract][Full Text] [Related]
8. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.
Hsu TL; Tsai CK; Liu CY; Yeh CM; Lin FL; Hsiao LT; Liu YC; Chien SH; Wang HY; Ko PS; Lin TA; Chen WC; Chen PM; Liu JH; Gau JP; Liu CJ
Ann Hematol; 2024 Mar; ():. PubMed ID: 38472362
[TBL] [Abstract][Full Text] [Related]
9. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.
Gonsalves WI; Buadi FK; Ailawadhi S; Bergsagel PL; Chanan Khan AA; Dingli D; Dispenzieri A; Fonseca R; Hayman SR; Kapoor P; Kourelis TV; Lacy MQ; Larsen JT; Muchtar E; Reeder CB; Sher T; Stewart AK; Warsame R; Go RS; Kyle RA; Leung N; Lin Y; Lust JA; Russell SJ; Zeldenrust SR; Fonder AL; Hwa YL; Hobbs MA; Mayo AA; Hogan WJ; Rajkumar SV; Kumar SK; Gertz MA; Roy V
Bone Marrow Transplant; 2019 Mar; 54(3):353-367. PubMed ID: 29988062
[TBL] [Abstract][Full Text] [Related]
10. Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma.
Bao A; Zhao Q; Kudalkar R; Rodriguez J; Sharma N; Bumma N; Devarakonda SS; Khan AM; Umyarova E; Rosko AE; Benson D; Cottini F
Front Oncol; 2023; 13():1216461. PubMed ID: 37554170
[TBL] [Abstract][Full Text] [Related]
11. Role of Stem Cell Transplantation in Multiple Myeloma.
Devarakonda S; Efebera Y; Sharma N
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670709
[TBL] [Abstract][Full Text] [Related]
12. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.
Cornell RF; Kassim AA
Bone Marrow Transplant; 2016 Apr; 51(4):479-91. PubMed ID: 26726946
[TBL] [Abstract][Full Text] [Related]
13. Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).
Bergin K; Wellard C; Augustson B; Cooke R; Blacklock H; Harrison SJ; Ho J; King T; Quach H; Mollee P; Walker P; Moore E; McQuilten Z; Wood E; Spencer A;
Bone Marrow Transplant; 2021 Oct; 56(10):2533-2543. PubMed ID: 34011965
[TBL] [Abstract][Full Text] [Related]
14. Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Bygrave C; Pawlyn C; Davies F; Craig Z; Cairns D; Hockaday A; Jenner M; Cook G; Drayson M; Owen R; Gregory W; Morgan G; Jackson G; Kaiser M
Br J Haematol; 2021 May; 193(3):551-555. PubMed ID: 32524584
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis.
Chen YH; Fogel L; Sun AY; Yang C; Patel R; Chang WC; Chen PH; Jhou HJ; Chen YC; Dai MS; Lee CH
Diagnostics (Basel); 2024 May; 14(10):. PubMed ID: 38786328
[TBL] [Abstract][Full Text] [Related]
16. Increased PD-1 Expression on Circulating T Cells Correlates with Inferior Outcome after Autologous Stem Cell Transplantation.
Richter S; Böttcher M; Stoll A; Zeremski V; Völkl S; Mackensen A; Ekici AB; Jacobs B; Mougiakakos D
Transplant Cell Ther; 2024 Jun; 30(6):628.e1-628.e9. PubMed ID: 38460727
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant.
Tun AM; Wang Y; Matin A; Inwards DJ; Habermann TM; Micallef I; Johnston PB; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Tun HW; Cerhan JR; Witzig TE; Nowakowski GS; Ansell SM
Hemasphere; 2023 Apr; 7(4):e869. PubMed ID: 37034004
[TBL] [Abstract][Full Text] [Related]
18. Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation.
Weber D; Jenq RR; Peled JU; Taur Y; Hiergeist A; Koestler J; Dettmer K; Weber M; Wolff D; Hahn J; Pamer EG; Herr W; Gessner A; Oefner PJ; van den Brink MRM; Holler E
Biol Blood Marrow Transplant; 2017 May; 23(5):845-852. PubMed ID: 28232086
[TBL] [Abstract][Full Text] [Related]
19. Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation.
Xu J; Yan W; Fan H; Liu J; Li L; Du C; Deng S; Sui W; Xu Y; Qiu L; An G
Ann Hematol; 2023 Nov; 102(11):3195-3204. PubMed ID: 37679605
[TBL] [Abstract][Full Text] [Related]
20. Effect of transplanted cells with CD184 and CD26 expressions and reconstitution of CD3+ lymphocyte population on long-term survival after autologous hematopoietic stem cell transplantation for multiple myeloma.
Kopinska A; Krawczyk-Kulis M; Wieczorkiewicz-Kabut A; Koclega A; Jagoda K; Dziaczkowska-Suszek J; Helbig G
Exp Hematol; 2023 Nov; 127():52-58.e1. PubMed ID: 37666354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
